BioLineRX Ltd. · TASE:BLRX
BioLineRX — Investor Presentation (January 2014)
41 slides from BioLineRX's investor presentation, January 2014

Slide 1: Company Presentation
Company Presentation January 2014

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

Slide 3: BioLineRx's Value Proposition
BioLineRx’s Value Proposition • Multiple shots on goal • Strategic relationships and access to Israeli technology • Two assets in pivotal studies during next 12 months • Two pharma assets regulated as devices • Several meaningful value inflection points in 2014 3

Slide 4: Our Business Model
Our Business Model Identify promising Conduct Feasibility Develop through Partner projects Testing` clinical stages • Strong scientific • Validate results of • Accelerated • Continued clinical basis inventors development development, if • High chance of program needed • Resolve main regulatory appro

Slide 5: Our Project Infrastructure Support
Our Project Infrastructure Support Expert Medical and Project Clinical Team Managers BD In-licensing and Pre-Clinical Out-licensing Team Multiple Projects Chemistry Team (Organic, Analytical, Intellectual Bioanalytical, Property Experts Formulation) Regulatory Affairs Team 5

Slide 6: Main Pipeline Assets
Main Pipeline Assets Pre-Clinical Phase Ill Partners Ventricular remodeling post-AMI Skin lesions Stem-cell mobilization Inflammatory bowel disease (IBD) rts — Hepatitis C (HCV) —_— = § 7 Collaboration with CTTQ for Chinese market Type 1 diabetes > Collaboration with JHL for Chinese and Southeast As

Slide 7: Selected Programs
SELECTED PROGRAMS 7

Slide 8: BL-1040: First-in-Class Myocardial Implant
BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR PREVENTION OF VENTRICULAR REMODELING FOLLOWING AMI Out-licensed to Ikaria Inc. and being developed as Bioabsorbable Cardiac Matrix (BCM) 8

Slide 9: BL-1040 Highlights
BL-1040 Highlights • Indication: Cardiac remodeling post-AMI • Mode of Action: Provides support to ischemic tissue during healing • Status: CE Mark registration trial – Results expected in 2014 • Partnered with Ikaria Inc. – Total deal structure $282.5 million; $17 million already received; 11-15% r

Slide 10: Unmet Medical Need
Unmet Medical Need Vessel occlusion Tissue damage Successfully treated with PCI and stents No sufficiently effective treatment for myocardial damage 10

Slide 11: How Does BL-1040 Work?
How Does BL-1040 Work? Infarct related artery injection Deposits into infarcted tissue Upon contact with infarcted tissue, turns from liquid into gel Gel-like scaffold provides mechanical support to damaged tissue Transitions to liquid and exits the body within 6 weeks 11

Slide 12: BL-1040 Prevents Structural Changes
BL-1040 Prevents Structural Changes Porcine AMI model, day 60 Dilated left Normal size ventricle left ventricle Normal LV Thin LV wall wall Untreated BL-1040 12

Slide 13: BL-1040 Pilot Study Results
BL-1040 Pilot Study Results • Designated as device by regulatory authorities (including FDA) • Pilot study in Europe – completed January 2010 – 27 patients, safety and preliminary efficacy in patients with primary MI at high risk for LV remodeling • 9 sites: 6 in Germany, 3 in Belgium • Trial result

Slide 14: BL-1040 Clinical Development Program
BL-1040 Clinical Development Program • Current development program includes two pivotal trials – CE Mark Registration trial for European approval – Second pivotal trial for US approval • Pivotal CE Mark Registration trial progressing at full steam – ~70 sites currently active in nine countries (incl

Slide 15: BL-8040: Best-in-Class CXCR4 Antagonist
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF HEMATOLOGICAL CANCERS 15

Slide 16: BL-8040 Highlights
BL-8040 Highlights • Indications: Acute myeloid leukemia (AML) & other hematological cancers • Mode of Action: CXCR4 antagonism – CXCR4 over-expressed in >70% of tumors, and correlates with disease severity. • Status: Phase II trial ongoing • Product Highlights: – Orphan designation received from FD

Slide 17: AML – Treatment and Unmet Medical Need
AML – Treatment and Unmet Medical Need • AML is most common acute leukemia in adults – Over 60,000 new cases recorded worldwide in 2010, growing to 130,000 by 2020 – 14,000 cases of AML diagnosed in the US in 2012 • AML has poor prognosis – less than 25% five-year survival – Over 10,000 fatalities f

Slide 18: BL-8040 Compared with Mozobil
BL-8040 Compared with Mozobil CXCL12 serum levels BL-8040 12 mg/kg BL-8040 0.11 BL-8040 0.167 Number of Neutrophils Mozobil 3.2 mg/kg BL-8040 0.22 Mozobil 0.11 Mozobil 0.167 Mozobil 0.22 Time post BL-8040/Mozobil injection Time post BL-8040/Mozobil injection 18

Slide 19: BL-8040 Mechanism Of Action
BL-8040 Mechanism Of Action • BL-8040 binds CXCR4 with high affinity (1-2 nM) • BL-8040 has long receptor occupancy (>24 hours) resulting in the extended inhibition of CXCR4 • BL-8040 is an inverse agonist of CXCR4 • BL-8040 induces apoptosis of tumor cells that are dependent on CXCR4 for survival •

Slide 20: Current BL-8040 Phase II Study in AML
Current BL-8040 Phase II Study in AML • Study summary – Open-label study under IND carried out at multiple centers in the US and Israel – Relapsed or refractory AML patients (up to 50 patients) • Study design – Dose escalation phase - up to 5 escalating doses (0.5-1.5 mg/kg) – Expansion phase of saf

Slide 21: BL-8040 AML Study Design
BL-8040 AML Study Design Relapse Treatment Follow Up BM biopsy: Day: 1 2 3 4 5 6 7 ------------------------------------------------------------ 30 Screening BL-8040 BL-8040 + Chemotherapy [Cytarabine (ARA-C)] Evaluation of response BM biopsy 21

Slide 22: Partial Results in AML Study
Partial Results in AML Study • Partial results, both as stand-alone therapy and in combination with high-dose Cytarabine (Ara-C) : – Safe at all doses tested to date (0.5, 0.75 and 1mg/kg) – Substantial mobilization of cancer cells from BM to peripheral blood – Evidence for robust effect of canc

Slide 23: Anti-tumor effect of BL-8040 on FLT3-WT AML cells in-vitro
Anti-tumor effect of BL-8040 on FLT3-WT AML cells in-vitro • In-vitro effect of BL-8040 or AMD3100 -/+ ARA-C on the viability of human AML FLT-3-WT cells. * p<0.05 vs. control ** p<0.05 vs. ARAC alone 23 M. Abraham et al., Unpublished data

Slide 24: Anti-tumor effect of BL-8040 on FLT3-ITD AML cells in-vitro
Anti-tumor effect of BL-8040 on FLT3-ITD AML cells in-vitro • In-vitro effect of BL-8040 or AMD3100 -/+ ARA-C on the viability of human AML cells with the FLT3-ITD mutation. * p<0.05 vs. control ** p<0.05 vs. BL8040 alone 24 M. Abraham et al., Unpublished data

Slide 25: BL-8040 (BKT140) Inhibits Proliferation
BL-8040 (BKT140) Inhibits Proliferation * VS. Mozobil (AMD3100) and BMS-936564 (DMX-1338) * American Association for Cancer Research 25

Slide 26: Stem Cell Mobilization: Additional Study Planned
Additional Study Planned • Stem cell mobilization study to start in H1 2014; results expected in H2 2014 4000 BKT140 Mobilization of Progenitors Number of progenitors per 1 ml of blood 3500 AMD3100 3000 GCSF BL-8040 + G-CSF 2500 BKT140+GCSF 2000 AMD3100+GCSF Mozobil + G-CSF 1500 1000 BL-8040 500 G-C

Slide 27: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease
BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE 27

Slide 28: BL-7010: Polymeric Binder for Celiac Disease
BL-7010: Polymeric Binder for Celiac Disease • Indication: Celiac disease • Status: Phase I/II commenced in December 2013 • MoA: Non-absorbable polymer with high affinity to gliadins (the immunogenic peptides contained in gluten) • Product Highlights – Prevents pathological damage to small intestine

Slide 29: Celiac Disease – Large Unmet Medical Need
Celiac Disease – Large Unmet Medical Need • 1% of world’s population suffers from celiac disease – Number underestimated due to lack of awareness/diagnostic tools • Market projected to reach $8 billion by 2019 • No current pharmacological agents approved for celiac – Only treatment option is life-lo

Slide 30: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides
BL-7010 Prevents Formation of Gliadin’s Immunogenic Peptides Gluten Gluten BL-7010 Copolymer of sodium styrene sulfonate (SS) and 2-hydroxyethyl methacrylate (HEMA) Gliadin Enterocytes BL-7010 demonstrates distinguished specificity towards gliadin Small intestinal damage with loss of absorptive vill

Slide 31: BL-7010 Maintains Normal Structure of GI
BL-7010 Maintains Normal Structure of GI non-sensitized Gluten-sensitized Gluten-sensitized mice mice mice + BL-7010 Villus-to-crypt ratio 5.96 ± 1.23 2.58 ± 0.43 4.89 ± 1.51 31

Slide 32: BL-7010 Clinical Program Overview
BL-7010 Clinical Program Overview Two studies in celiac disease patients are planned in 2013-2014: • First-in-man study in celiac patients (commenced) – Single and repeated ascending dose study – Safety endpoints, no efficacy endpoints – Assessment of systemic exposure • Efficacy study in celiac pat

Slide 33: BL-7010 First-In-Man Study in Celiac Patients
BL-7010 First-In-Man Study in Celiac Patients BL-7010 phase I/II study consists of 2 parts: • Part 1: Single ascending administration study – Two alternating cohorts; 8 patients each (6 on BL-7010 and 2 on placebo) – Up to 6 escalating administrations – Population - well controlled celiac patients =

Slide 34: BL-5010: Novel Formulation for Non-Surgical Removal of Skin Lesions
BL-5010: A NOVEL FORMULATION FOR NON-SURGICAL REMOVAL OF SKIN LESIONS, EMBEDDED WITHIN NEW APPLICATOR PEN (BL-5010P) - FOR TOPICAL USE 34

Slide 35: BL-5010 Highlights
BL-5010 Highlights • Novel formulation for non-surgical removal of skin lesions • Status: Commencement of pivotal study expected in Q1 2014 • Product Highlights: – Medical device classification in EU – Single application office-based treatment – Pilot study completed with outstanding results • ~97%

Slide 36: BL-5010 Roadmap
BL-5010 Roadmap • Pivotal CE Mark Registration study to commence in Q1 2014 – Bridging study of BL-5010 pen-like applicator in seborrheic keratosis – Regulatory submissions have been completed – Study results are expected H2 2014 – Commence CE-mark registration process in H2 2014 • Clinical study in

Slide 37: Corporate
CORPORATE 37

Slide 38: Financial Summary
Financial Summary • Available cash as of September 30, 2013 - ~$20.3 million − Annual burn rate ~$12 million − Cash expected to last into mid-2015 • Number of employees - 43 • Capital structure (on basis of ADSs) − 24.1 million outstanding – basic capital − 29.6 million outstanding – fully diluted c

Slide 39: Analyst Coverage
Analyst Coverage BioLineRx Ltd. is followed by the analysts listed below: Analyst Firm Raghuram Selvaraju Aegis Capital Corp. Robert Hazlett Roth Capital Partners, LLC Robin Davison; Jason Zhang Edison Investment Research Please note that any opinions, estimates or forecasts regarding BioLineRx Ltd.

Slide 40: 2014 Major Milestones
2014 Major Milestones BL-9020 (Type 1 Diabetes) collaboration with JHL √ BL-5010 (Skin Lesions) pivotal EU study initiation BL-8020 (HCV) phase 1/2 partial results BL-7010 (Celiac Disease) phase 1/2 partial results* BL-8040 (AML) phase 2 partial results* BL-8040 (Stem Cell Mobilization) phase 1 init

Slide 41: Bench1o Bedoideto Patner
Bench1o Bedoideto Patner BIOLINEM ><
Source: Internet Archive copy of biolinerx.com
More decks from BioLineRX Ltd.
Investor Presentation (July 2026)39 slides · July 2026
Q1 2026 Earnings Presentation28 slides · May 27, 2026
Technical Presentation (December 2020)14 slides · Dec 16, 2020
Technical Presentation (December 2020)49 slides · Dec 16, 2020
Investor Presentation (February 2019)31 slides · Feb 4, 2019
Investor Presentation (October 2018)30 slides · Oct 1, 2018